Please login to the form below
UCB’s antiepileptic drug gains new US indication
FDA approves Briviact as a monotherapy to treat POS
FDA approves Medtronic's tablet-controlled pain device
The Intellis system can be programmed via a Samsung's Galaxy S2
With US approval, GSK now needs rapid uptake for COPD triple
Aims to quickly launch the predicted blockbuster to revive its R&D portfolio
NICE says OK to Opdivo for lung cancer via CDF
Comes after BMS drops the price of its PD-1 inhibitor
MSD's Keytruda wins new bladder cancer indication in Europe
Will treat locally advanced or mUC patients
AbbVie and Roche plan Venclexta combo filings in leukaemia
MURANO trial shows the duo’s treatment extends PFS
CHMP backs maintenance therapy for Tesaro's Zejula
Swiss biotech's PARP inhibitor recommended for approval in ovarian cancer
Bayer bags speedy US approval for lymphoma drug Aliqopa
FDA decision sets the pharma firm up for a showdown with Gilead's Zydelig
GSK's Shingrix sails through FDA advisory committee
Shingles vaccine data proved safe and effective, says the panel
SMC gives green light for Amgen’s Kyprolis
The committee also gives verdict on three other products
-
Facing the new wave of biosimilarsDon’t drown out the patient voice, says advocacy group
-
Promoting off-label use: where to draw the line?Looking at the trend among EU member states to actively promote the off-label use of medicines
-
Roche faces prospect of second Rituxan biosimilar in USFDA begins its review of Sandoz's version of the immunotherapy treatment
-
GSK preps COPD filing for asthma pioneer NucalaMoves despite reporting mixed data for the treatment earlier this year
-
NICE: We're the institute of 'yes'But Meindert Boysen says affordability conversations with pharma need to happen earlier
-
UK is first to receive Roche's rare lung cancer drug Alecensa made available under MHRA's early access scheme
-
Sarepta eyes FDA filing for DMD drug golodirsen after positive trialThe exon-skipping drug raised functional dystrophin levels
-
PharmaLex strikes up AI collaboration with VolvThe duo will develop pharmacovigilance products and services
-
Dismay as NICE turns down first-line use of AZ's FaslodexSays evidence isn’t convincing for use in post-menopausal women
Latest regulatory appointments
-
NDA Group appoints new vice president Dr Werner Van den Eynde will also lead its advisory board
-
Dr Desiree Luthman joins Verona PharmaShe takes up its vice president position
-
IFPMA appoints Fumie Griego as assistant director generalShe joins the global pharma association from Merck KGaA
-
Ergomed appoints CEO of PrimeVigilanceDr Jan Petracek to drive pharmacoviglance business
-
Greenleaf Health appoints drug and biological products principal
Dr John Jenkins joins the FDA regulatory consulting firm
Featured jobs
- Principal Medical Writer, Medical Communications, London
-
Excellent package
-
Account Director
-
Salary TBC
-
Medical Writer
-
Competitive Salary
- Junior - Mid Level Medical Copywriter, Healthcare Advertising Ag...
-
£30-35, 000 according to skills and experience
- Senior Medical Writer, Medical Communications, London
-
Excellent package
- Editorial Director, Medical Communications, London
-
Excellent package
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
- Director of Rare Diseases, Healthcare Agency, London
-
Excellent Package
-
Programme Director
-
Salary TBC
Subscribe to our email news alerts
- Novartis looks outside pharma for digital transformation
- Merck to co-lead new oncology big data alliance
- Sandoz says Humira biosimilar clears clinical hurdle
- GSK closes in on EU approval for triple COPD therapy
- Amgen's Mvasi is first FDA-approved cancer biosimilar
- Roche faces prospect of second Rituxan biosimilar in US
PMHub
wethepeople
wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...
Latest intelligence
- Why AI might be the rep’s best friend
- When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...
- How Transparent Is Transparency?
- The second annual publication of transfer of value (TOV) data has just been publically disclosed. For those of you that it passed by, it seems to have generated very little...
- LEO: Patients benefit from transparency
- Paving the way for openness in pharma...
Quick links
Infographics
